www.alk.net
  • Patients
    • What is allergy
      • House dust mite allergy
        •  
      • Pollen allergy
        •  
      • Living with allergy
        •  
      • Socio-economic impact
        •  
      •  
    • What is allergic asthma
      •  
    • How is allergy diagnosed
      •  
    • Treating allergy
      •  
    •  
  • Healthcare Professionals
    • Treating allergy and asthma
      •  
    • Products
      •  
    • Adverse reactions
      •  
    • Initiation of treatment
      •  
    • Clinical trials
      •  
    •  
  • R&D
    • R&D pipeline
      •  
    • Understanding immunotherapy
      •  
    • Research
      •  
    • Congress activities
      •  
    • Clinical data sharing
      •  
    •  
  • Careers
    • Working at ALK
      •  
    • Vacant positions
      •  
    •  
  • Investors
    • Overview
      •  
    • Financial reporting
      • Risk management
        •  
      • Reporting standards
        •  
      • Auditors
        •  
      •  
    • Governance
      • IR policy
        •  
      • Board of Management
        •  
      • Board of directors
        •  
      • Annual general meeting
        •  
      • Annual general meeting (DK)
        •  
      •  
    • News & Events
      • Company Releases
        •  
      • Company releases (DK)
        •  
      • Webcasts & presentations
        •  
      • Investor calendar
        •  
      •  
    • The Share
      • Dividend history
        •  
      • Analyst coverage
        •  
      • Analyst estimates
        •  
      • Shareholder information
        •  
      • Authorizations
        •  
      • ADR Programme
        •  
      •  
    • Contact IR
      •  
    • Board of Management
      •  
    • Board of directors
      •  
    • AGM
      •  
    • AGM (DK)
      •  
    • Nyheder
      •  
    • Nyheder (EN)
      •  
    •  
  • Media
    •  
  • About
    • ALK at a glance
      •  
    • CSR
      •  
    • Production
      •  
    • Global presence
      •  
    • Organisation
      •  
    • History
      •  
    • Values
      •  
    • Owners
      •  
    •  
  • Select country
    •  
Search

Investor Relations

Nyheder

Vis alle

  • Post date: 11. Aug. 2021
    Six-month interim report (Q2) 2021
    Read more
  • Post date: 09. Aug. 2021
    ALK opjusterer forventningerne til 2021
    Read more
  • Post date: 05. Aug. 2021
    Ændring i ALK’s bestyrelse
    Read more
  • Post date: 05. Aug. 2021
    Dato for offentliggørelse af delårsrapport for første halvår (Q2) 2021 for ALK og webcast
    Read more
  • Post date: 30. Juli 2021
    ALK og Grandpharma indgår partnerskab om markedsføring af den første adrenalinpen i Kina
    Read more
  • Post date: 05. Maj 2021
    Three-month interim report (Q1) 2021
    Read more

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Udskriv

    Udskriv

  • Del

    Del

  • English

    English

  • Søg

    Søg




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved